Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management.

ABSTRACT: Epilepsy, a common multifactorial neurological disease, affects about 69 million people worldwide constituting nearly 1% of the world population. Despite decades of extensive research on understanding its underlying mechanism and developing the pharmacological treatment, very little is known about the biological alterations leading to epileptogenesis. Due to this gap, the currently available antiepileptic drug therapy is symptomatic in nature and is ineffective in 30% of the cases. Mounting evidences revealed the pathophysiological role of neuroinflammation in epilepsy which has shifted the focus of epilepsy researchers towards the development of neuroinflammation-targeted therapeutics for epilepsy management. Markedly increased expression of key inflammatory mediators in the brain and blo

SUBMITTER: Rawat C 

PROVIDER: S-EPMC6822425 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature